PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM
    2.
    发明申请
    PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM 有权
    具有NPY Y5受体拮抗剂的哌啶和吡咯烷衍生物

    公开(公告)号:US20110319412A1

    公开(公告)日:2011-12-29

    申请号:US13254750

    申请日:2010-03-05

    摘要: The present invention discloses novel piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), a pharmaceutically acceptable salt or a solvate thereof: wherein A is substituted or unsubstituted monocyclic aryl or monocyclic heterocyclyl; X is a single bond or C(═O); Y is a single bond, CR5R6NR7 or C(═O)NR7; R1 and R2 are independently hydrogen or substituted or unsubstituted alkyl; R3 is substituted or unsubstituted aryl or heterocyclyl; R4 is halogen, substituted or unsubstituted alkyl, alkoxy, aryloxy or heterocyclyloxy, etc.; p is an integer of 0 to 2; q is 0 or 1; m is 0 or 1; n is an integer of 0 to 5; and B is aromatic carbocycle, monocyclic heterocycle or bicyclic fused hetero ring.

    摘要翻译: 本发明公开了具有NPY Y5受体拮抗作用的新型哌啶和吡咯烷衍生物。 具体地说,本发明公开了由式(I)表示的化合物,其药学上可接受的盐或溶剂合物:其中A是取代或未取代的单环芳基或单环杂环基; X是单键或C(= O); Y是单键,CR5R6NR7或C(= O)NR7; R1和R2独立地为氢或取代或未取代的烷基; R3是取代或未取代的芳基或杂环基; R4是卤素,取代或未取代的烷基,烷氧基,芳氧基或杂环氧基等; p为0〜2的整数。 q为0或1; m为0或1; n为0〜5的整数, 和B是芳族碳环,单环杂环或双环稠合杂环。

    Cyclohexane derivative having NPY Y5 receptor antagonism
    4.
    发明授权
    Cyclohexane derivative having NPY Y5 receptor antagonism 失效
    具有NPY Y5受体拮抗作用的环己烷衍生物

    公开(公告)号:US08653125B2

    公开(公告)日:2014-02-18

    申请号:US13254702

    申请日:2010-03-05

    摘要: The present invention discloses novel cyclohexane derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), or a pharmaceutically acceptable salt or a solvate thereof: wherein A is substituted or unsubstituted aryl or heterocyclyl; a combination of X and Y is a combination selected from (X, Y)═(C(═O)N(R1), C(═O)N(R2)), (C(═O)N(R1), imidazole-1,3-diyl), (N(R1), C(═O)N(R2)), (O, C(═O)N(R2)), (C(R3)(R4), N(R2)) or (a single bond, C(═O)N(R2)); R1, R2 and R3 are independently hydrogen or substituted or unsubstituted alkyl; R5 is substituted or unsubstituted aryl or heterocyclyl; R6 is halogen, oxo, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy; m is 0 or 1; and n is an integer of 0 to 5; and B is aromatic carbocycle, monocyclic heterocycle or fused bicyclic heterocycle.

    摘要翻译: 本发明公开了具有NPY Y5受体拮抗活性的新型环己烷衍生物。 具体而言,本发明公开了式(I)表示的化合物或其药学上可接受的盐或溶剂化物:其中A为取代或未取代的芳基或杂环基; X和Y的组合是选自(X,Y)=(C(= O)N(R1),C(= O)N(R2)),(C(= O)N(R1) 咪唑-1,3-二基),(N(R1),C(= O)N(R2)),(O,C(= O)N(R2)),(C(R3) (R2))或(单键,C(= O)N(R2)); R1,R2和R3独立地是氢或取代或未取代的烷基; R5是取代或未取代的芳基或杂环基; R 6是卤素,氧代,取代或未取代的烷基,取代或未取代的烷氧基,取代或未取代的芳氧基; m为0或1; n为0〜5的整数。 和B是芳族碳环,单环杂环或稠合双环杂环。